They Call It a Lottery Ticket. The Data Says Otherwise | D.A. Wallach on The Hidden Alpha of Biotech

The podcast explores biotech investing, particularly the factors that contribute to active alpha in the space. Venture capitalist D.A. Wallach explains that valuing biotech companies requires domain-specific expertise due to the uncertainty of products reaching the market. He introduces a bag-of-options framework, emphasizing the importance of base rates and total addressable market when evaluating potential drugs. Wallach notes that biotech faces competition from other risky sectors like AI for investor interest, and discusses the impact of the pandemic on biotech enthusiasm and valuations. He highlights the role of specialist hedge funds and venture firms in driving returns and actively building companies, and touches on the increasing trend of conducting clinical trials in China due to efficiency and cost advantages.